- within Food, Drugs, Healthcare and Life Sciences topic(s)
- within Antitrust/Competition Law and Immigration topic(s)
Heading into the J.P. Morgan Healthcare Conference, the conversation will center on accelerated deal flow, selective but improving capital access, and disciplined execution. Strategic buyers face patent cliffs and pipeline gaps, investors are seeking risk‑adjusted structures, and operators are focused on manufacturing readiness and payer dynamics. Antitrust scrutiny remains a planning variable, but it is shaping deal design more than stopping transactions. For companies, investors, and boards, the practical takeaway is to prepare for speed with structure: come to San Francisco with clean data rooms, credible milestones, and flexible transaction playbooks.
Dealmaking Outlook: Momentum With Discipline
After two years of valuation reset, buyer and seller expectations have converged enough to support an active 2026 calendar. Large biopharma appears ready to transact across late‑stage assets and revenue‑adjacent bolt‑ons, while mid‑cap and venture‑backed companies are running dual‑track processes that preserve optionality among sale, IPO, and reverse merger. Services and enablement platforms—particularly CDMOs, specialty distributors, and technology‑enabled clinical operations—remain in focus, though capacity and customer concentration will influence pricing and terms.
While the tone is constructive, selectivity is high. Buyers are concentrating on programs with near‑term catalysts and on modalities with more durable economics, favoring biologics and targeted therapies over small molecules that face faster generic erosion. Divestitures and carve‑outs are supplying attractive platforms as larger companies sharpen portfolios. The best‑positioned sellers are those that have separation plans ready, realistic transition services, and a clear story for post‑close value creation.
Key practical implications include the need to budget more time from signing to close, to pre‑plan remedies where market overlaps exist, and to anchor valuation to executable operating plans rather than peak‑sales headlines.
Financing Conditions: More Avenues, Higher Bar
Capital access is improving but remains tiered. Late‑stage and commercial‑stage companies with visible milestones can execute follow‑ons, at‑the‑market programs, and structured PIPEs. IPOs are returning selectively when paired with crossovers and strong fundamentals. Convertible notes are attractive again as rate volatility eases, offering lower cost of capital for issuers with credible timelines. For commercial stage companies, royal monetization will continue to be a potential source of capital.
Private credit continues to expand across healthcare, particularly for acquisitions and revenue‑stage growth. Lenders are more comfortable with specialty product cash flows, but covenants and reporting expectations are tighter. Venture debt is available for earlier‑stage companies, usually linked to equity raises and milestone‑based draws.
For issuers, the theme is preparation. Clear use of proceeds, disciplined burn, and milestone visibility differentiate offerings. For investors, underwriting should incorporate execution and access risk alongside clinical probabilities.
Hot Therapeutic and Modality Themes
Investors and strategics will focus on areas with strong clinical momentum and scalable manufacturing. Radiopharmaceuticals are a marquee theme (Aktis Oncology announced a $318 million upsized IPO on January 9th), with particular attention to isotope supply, logistics, and site readiness. Cardiometabolic programs, including GLP‑1 adjacencies and oral formulations, are driving partnering and tuck‑ins, with secondary effects across medtech and services. Neuroscience is resurgent as biomarkers and targeted mechanisms improve probability of success. Autoimmune and inflammatory diseases remain active as precision approaches expand addressable populations. Cell and gene therapies continue to mature commercially, with buyers underwriting vector supply, comparability plans, and outcomes‑based access models.
Expect diligence to probe manufacturability as much as science. Buyers will price validated capacity, tech‑transfer plans, quality history, and redundancy into deal terms through holdbacks, milestones, and post‑close investment commitments.
Medtech and Diagnostics: Focused Consolidation and AI Enablement
Medtech consolidation is likely to continue in surgical robotics, interventional cardiology, and neuromodulation, where category leadership and hospital integration drive scale advantages. Diagnostics activity will concentrate on high‑impact tests with clear reimbursement, while platform rationalization continues in crowded categories. AI‑enabled devices and clinical decision support will feature prominently, but acquirers will test data provenance, model performance across subpopulations, and postmarket monitoring capabilities as part of value and risk assessment.
Hospital capital spending and supply chain reliability will influence timing and valuation. Sellers with resilient vendor footprints, field service models, and cybersecurity credentials will stand out.
Clearance and Antitrust: A Deal‑Design Constraint, Not a Stop Sign
Regulatory review is a gating factor and will shape structure and timing, especially in narrow therapeutic overlaps, platform combinations, or vertical integrations involving data, distribution, and pharmacy channels. Agencies are scrutinizing both current overlaps and potential future competition, pushing parties to consider clean structural remedies and credible divestiture buyers. Coordination across U.S., EU, and U.K. processes can lengthen timelines.
Practical implications for 2026 transactions include earlier overlap mapping, remedy planning before signing, and tighter drafting around efforts standards, reverse termination fees, and outside dates. Combinations touching PBM, specialty pharmacy, or data assets should assume deeper analysis of foreclosure and information‑sharing risks and invest in governance designs that make pro‑competitive commitments credible.
Innovative Structures and Partnering Models
Structure will be a competitive differentiator this year. Expect more options‑to‑acquire and staged deals that tie valuation to clinical or regulatory readouts while providing sellers with capital and strategic support. Contingent value rights and earnouts will remain common to bridge gaps; definitions are tightening to reduce disputes and to reflect realities like supply constraints or staged launches. Regional partnerships, co‑development and profit‑share alliances, and asset‑centric spinouts will be used to align capital with expertise and market access.
Royalty monetizations and synthetic royalty features within M&A can optimize cost of capital by sharing economics. Reverse mergers will remain a path for late‑stage private companies to reach public investors, particularly where the public target brings cash and a clean cap table.
Cross‑Border and Geopolitical Considerations
Cross‑border interest remains strong, but parties are navigating tighter foreign investment reviews, export controls, and data‑transfer restrictions. Some bidders are opting for minority stakes, joint ventures, or asset purchases when full control raises review complexity. Supply chain resilience—especially for isotopes, vectors, and critical components—is a valuation and risk‑allocation issue. Buyers should stress‑test sourcing strategies and include redundancy and localization plans in integration models.
Execution and Diligence Priorities
Execution risk is the swing factor in many 2026 deals. Diligence will extend beyond clinical data to manufacturing readiness, quality system maturity, and commercial access planning. Investors and acquirers will test:
- Supply chain durability, including isotope and vector availability, CDMO capacity, and tech‑transfer feasibility.
- Data rights and AI provenance, including consents, licenses, ownership of code and weights, and cybersecurity posture.
- Payer access assumptions, including formulary dynamics, patient affordability strategies, and the first‑year launch plan.
- Separation and integration readiness, from transition services to pharmacovigilance handoffs and distribution continuity.
Well‑designed post‑close operating plans and transparent milestone maps will support valuation and shorten the path to value capture.
What to Watch and Prepare For at J.P. Morgan
Stakeholders can use the conference to pressure‑test assumptions and to position for near‑term action.
- For companies: Bring a crisp partnering thesis, validated CMC timelines, and a capital plan that ties directly to upcoming catalysts. Keep data rooms current and potential solutions pre‑baked where overlaps are foreseeable.
- For investors: Focus on teams that price execution risk realistically, show manufacturing and access readiness, and use structures that align incentives through uncertainty. Expect greater dispersion in outcomes based on operational follow‑through.
- For boards: Calibrate oversight for speed with accountability. Ensure process discipline for structured transactions, align management incentives to integration and milestone delivery, and plan communications that set credible, time‑bound expectations.
Bottom Line
The 2026 conversation at J.P. Morgan will be about acceleration with structure. Dealmaking is set to broaden, capital markets are open for prepared issuers, and partnering tools can bridge valuation and risk. Clearance scrutiny and execution realities will determine pace and pricing, not whether deals get done. Teams that arrive with clean facts, flexible structures, and a credible plan to make and deliver will find ample opportunity to transact—and to create durable value across healthcare and life sciences.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
